Onvapegleukin alfa - Ascendis Pharma
Alternative Names: TransCon IL-2 b/g; TransCon IL-2 β/γ; TransCon Interleukin 2 beta/gamma - Ascendis PharmaLatest Information Update: 03 Jan 2025
Price :
$50 *
At a glance
- Originator Ascendis Pharma
- Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
- Mechanism of Action Interleukin receptor common gamma subunit stimulants; Interleukin-2 receptor beta subunit agonists; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Squamous cell cancer
- Phase I/II Solid tumours
Most Recent Events
- 13 Sep 2024 Efficacy, pharmacodyanmics and adverse events data from the phase I/II trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 13 Sep 2024 Efficacy data from a phase I/II IL Believe trial in Solid tumours released by Ascendis Pharma
- 03 Jun 2024 Pharmacodynamic and efficacy data from phase I/II trial in Solid tumor released by Ascendis Pharma